MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

BrancheGesundheitswesen

21.46

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.45

Max

21.47

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-3.8M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-2.84% downside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.46
Vorheriger Schlusskurs	21.46

Nachrichtenstimmung

By Acuity

50%

154 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Apr. 2026, 23:25 UTC

Wichtige Nachrichtenereignisse

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13. Apr. 2026, 22:45 UTC

Wichtige Nachrichtenereignisse

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13. Apr. 2026, 18:03 UTC

Ergebnisse

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13. Apr. 2026, 23:58 UTC

Ergebnisse

Review & Preview: Earnings Time -- Barrons.com

13. Apr. 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13. Apr. 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13. Apr. 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13. Apr. 2026, 21:26 UTC

Wichtige Nachrichtenereignisse

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13. Apr. 2026, 21:23 UTC

Ergebnisse

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13. Apr. 2026, 21:16 UTC

Ergebnisse

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

13. Apr. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13. Apr. 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13. Apr. 2026, 19:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13. Apr. 2026, 19:27 UTC

Market Talk

Wichtige Nachrichtenereignisse

Correction to Precious Metals Market Talk on April 9

13. Apr. 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13. Apr. 2026, 18:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13. Apr. 2026, 18:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13. Apr. 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-2.84% Nachteil

12-Monats-Prognose

Durchschnitt 20.86 USD -2.84%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

154 / 348 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.